Sökning: WFRF:(Arvidson Johan 1953 )
> (2015-2019) >
Long-term outcome o...
Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT
-
- Kinch, Amelie, 1973- (författare)
- Uppsala universitet,Infektionssjukdomar
-
- Hallböök, Helene (författare)
- Uppsala universitet,Hematologi
-
- Arvidson, Johan, 1953- (författare)
- Uppsala universitet,Barnneurologi/Barnonkologi
-
visa fler...
-
- Sällström, Kalle (författare)
- Uppsala universitet,Infektionssjukdomar
-
- Bondeson, Kåre (författare)
- Uppsala universitet,Klinisk virologi
-
- Pauksen, Karlis (författare)
- Uppsala universitet,Infektionssjukdomar
-
visa färre...
-
(creator_code:org_t)
- 2017-08-23
- 2018
- Engelska.
-
Ingår i: Leukemia and Lymphoma. - : Informa UK Limited. - 1042-8194 .- 1029-2403. ; 59:5, s. 1172-1179
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- We studied retrospectively the outcome of Epstein-Barr virus (EBV)-related disease with EBV monitoring and preemptive rituximab to prevent post-transplant lymphoproliferative disorder (PTLD) in 319 consecutive allogeneic stem cell transplantations 2004-2012. Patients who received anti-thymocyte globulin (ATG) or alemtuzumab were regarded as high-risk for PTLD (n = 214). EBV DNAemia ≥1000 copies/mL plasma was observed in 50 (23%) of the high-risk patients. Thirty-three of the high-risk (15%) and one of the low-risk (1%) patients received rituximab, in combination with reduction of immunosuppression (n = 24) or chemotherapy (n = 4). Although rituximab was initiated only 5 d after first EBV load ≥1000 copies/mL, 85% of the rituximab-treated patients developed symptoms (lymphadenopathy 50%, fever 76%, and encephalitis/meningitis 12%). Response-rate to EBV treatment was 88%. Overall survival at 1- and 5-year was 71 and 52% for rituximab-treated patients, which was not inferior to all other patients post-transplant. In conclusion, rituximab therapy for EBV DNAemia does not affect long-term survival negatively.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- EBV
- PTLD
- allogeneic HSCT
- rituximab
- survival
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas